Syndax Pharmaceuticals Культура компании

Mr. Michael A. Metzger, M.B.A. has been the President and Chief Operating Officer of Syndax Pharmaceuticals, Inc. since May 5, 2015. Mr. Metzger served as the Chief Executive Officer, President and Chief Operating Officer of Tobira Therapeutics, Inc. since May 04, 2015. He served as the Chief Executive Officer of Regado Biosciences, Inc. since October 10, 2014 and served as its President since December 5, 2013 and Chief Operating Officer since December 5, 2013. He served as an Executive Vice President and Chief Operating Officer of Mersana Therapeutics, Inc. from April 20, 2011 to 2013, where he drove the establishment and management of key alliances and helped to architect the strategic direction, financing and growth of the business. Mr. Metzger served as the Chief Business Officer and Executive Vice President of Radius Health, Inc. from November 2013 to November 22, 2013. He also acted as an Advisor to Tobira during its subsequent sale to Allergan in 2016. He has operational and management expertise as well as a history of creating value through transactions. Mr. Metzger has nearly 20 years of experience within the life sciences and pharmaceuticals industries. He served as Senior Director of Business Development at Forest Laboratories, Inc. since 2006 and served as its Head of the Mergers & Acquisitions practice. From 2006 to 2011, Mr. Metzger held senior positions within business development and led mergers and acquisitions at Forest Laboratories, Inc., where he completed transactions with numerous specialty pharmaceutical and biotechnology companies. At Forest Laboratories, he spearheaded the mergers and acquisitions function and led the successful acquisition of Clinical Data, Inc. for $1.2 billion. Mr. Metzger served as Vice President of Corporate Development of Onconova Therapeutics, Inc. from 2001 to 2006. Mr. Metzger was responsible for Onconova's business development and financial initiatives. He served as Managing Director at MESA Partners, Inc. from 1997 to 2001, working primarily with healthcare and IT companies. Mr. Metzger is a finance professional with experience in venture capital, management consulting and companies within the Life Sciences industry. He has been a Director of CTI BioPharma Corp. since January 24, 2017. Mr. Metzger has been a Director of Tarveda Therapeutics, Inc. since June 19, 2017. He served as a Director of Regado Biosciences, Inc. since October 10, 2014. He served as a Director of Response Genetics, Inc. from December 2010 to November 20, 2013. Mr. Metzger holds an MBA in Finance from New York University Stern School of Business and a BA degree in Political Science from The George Washington University.

Dr. Peter Ordentlich, Ph. D., is the Founder of Syndax Pharmaceuticals, Inc. and has been its Chief Scientific Officer since September 2016 and served as its Chief Technology Officer since November 1, 2013 until August 2016. Dr. Ordentlich served as Vice President of Translational Medicine at Syndax Pharmaceuticals, Inc. from January 2012 to October 2013. Dr. Ordentlich is responsible for the scientific rationale and direction of nonclinical efforts related to the Syndax's projects. He served as Executive Director of Translational Science and Director of Scientific Affairs & Strategic Relations at Syndax Pharmaceuticals, Inc. from January 2011 to December 2011 and from January 2008 to December 2010 respectively. Prior to Syndax, Dr. Ordentlich was a Scientist at the Salk Institute in La Jolla, CA , where he worked to identify small molecules as potential therapeutics and evaluating synergistic combinations of histone deacetylases inhibitors and nuclear receptor ligands. Before returning to the Salk Institute, Dr. Ordentlich spent 5 years at X-Ceptor Therapeutics, where he led a group in assay development, high-throughput screening and lead optimization. His work with other members of the Evans laboratory, led to the identification and characterization of several proteins involved in nuclear receptor regulation including histone deacetylases 5 and 7 (HDAC5 and HDAC7) and novel isoforms of the co-repressor SMRT and SHARP. Dr. Ordentlich did his post-doctoral fellowship in investigating the molecular mechanisms involved in nuclear hormone receptor signaling. Dr. Ordentlich received his BA in Biochemistry and PhD in Immunology from the University of Pennsylvania.

Dr. Michael L. Meyers, M.D., Ph.D., has been Chief Medical Officer and Senior Vice President of Syndax Pharmaceuticals, Inc. since May 2016 and August 17, 2015 respectively and served as its Chief Development Officer since August 17, 2015 until May 2016. Dr. Meyers held a number of senior roles at Johnson & Johnson, a publicly traded company and served as Vice President of GU Oncology, Compound and Clinical Leader and Vice President of Oncology Scientific Innovation in Johnson and Johnson's London Innovation Centre. Dr. Meyers also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc., a privately held life sciences company, predecessor to Sanofi-Aventis U.S. LLC and worked in oncology clinical development at the Schering-Plough Research Institute. Dr. Meyers served on the Memorial Sloan Kettering Cancer Center faculty, specializing in Clinical Immunology and melanoma. He was elected to the American Osteopathic Association. Dr. Meyers completed his residency in Internal Medicine at Columbia Presbyterian Medical Center and his fellowship, where he served as Chief Fellow in Medical Oncology, at Memorial Sloan Kettering Cancer Center. He has M.D. and Ph.D. in Microbiology and Immunology from Albert Einstein College of Medicine in New York.

James Stutely serves as the Director Clinical Operations of Syndax Pharmaceuticals. James started at Syndax Pharmaceuticals in June of 2017. James currently resides in Greater Boston Area.

Jeannette Hasapidis serves as the Vice President Program Management of Syndax Pharmaceuticals. Jeannette started at Syndax Pharmaceuticals in September of 2016. Jeannette currently resides in Greater Boston Area.

Luke Albrecht serves as the Vice President, General Counsel and Secretary of Syndax Pharmaceuticals. Luke started at Syndax Pharmaceuticals in August of 2016. Luke currently resides in Greater New York City Area.

Michael Meyers serves as the Chief Medical Officer of Syndax Pharmaceuticals. Michael started at Syndax Pharmaceuticals in May of 2016. Michael currently resides in Greater New York City Area.

Robert Nordness serves as the Head of Pharmacovigilance of Syndax Pharmaceuticals. Robert currently resides in the Greater New York City Area.